AZ’s Make Or Break Moment Comes Down To Business Development
Executive Summary
AstraZeneca needs new assets to change investors’ dismal outlook for the company. With a new CEO installed, an R&D shakeup underway, and a new portfolio strategist joining in May, AstraZeneca will embark on an ambitious acquisition and partnering strategy in 2013.
You may also be interested in...
Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues
As AstraZeneca’s global product chief Marc Dunoyer moves on to the CFO job, he leaves a newly restructured, active, and decentralized dealmaking organization.
AZ’s Upbeat Pipeline Message Tarnished By Federal Probes, Poor Sales
AstraZeneca highlighted pipeline progress during its quarterly earnings call, but remained on the defensive as analysts questioned two newly disclosed U.S. federal inquiries and the promotion of Marc Dunoyer to CFO, as the Big Pharma struggles with falling sales and profits.
Venture Creation Story: The Early Days Of Moderna
From pioneering stem-cell work to trade secrets a la Coca-Cola, what it means when a company – in this case, the RNA therapeutics developer Moderna – comes through Flagship Ventures’ VentureLabs group.